Psychiatric Multi-omics and Neuroimaging Project

Recruiting

• Conditions: Mental Disorders; Healthy Control
• Interventions: Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids

• Registration Number: NCT06580860
• Lead Sponsor: mingjun Zhong

Brief Summary

This study focuses on the structure and function of the brain and gene expression in peripheral blood of patients with schizophrenia, to explore the interaction and influence between the three. Patients with mental disorders who have been recruited will take their medication regularly for 1 year and participate in baseline and follow-up assessments.

Detailed Description

The study seeks to identify possible biological markers of schizophrenia and the effects of gene-environment interactions on brain structural and functional networks. So we can help doctors and scientific researchers better understand the neuropathological basis of schizophrenia.

Study Timeline

• Study Start: 2016-01
• Status Verified: 2024-08
• Study First Submitted: 2024-08-28
• Study First Submitted QC: 2024-08-29
• Study First Posted: 2024-08-30
• Last Update Submitted: 2024-09-01
• Last Update Posted: 2024-09-05
• Primary Completion: 2025-12
• Study Completion: 2025-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 1899

Inclusion Criteria

• Age: 13-35 years old(Patients with healthy siblings can be extended to 14-35 years of age)
• Course of disease: <24 months
• Priority is given to patients who have never taken medicine or duration of drug use < 2 weeks
• No nuclear magnetic contraindications.

Exclusion Criteria

• Family history of psychotic disorders, history of psychoactive substances abuse, alcohol dependence, or nicotine dependence
• Have a major physical disease or infectious disease
• History of coma and serious neurological disease 4.MRI contraindications.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
PMNP-Healthy Norms	Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids	Healthy Norms
PMNP-Subclinical high-risk	Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids	Subclinical high-risk
PMNP-Schizophrenia and Psychosis	Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids	Schizophrenia and Psychosis patient
PMNP-MDD	Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids	major depressive disorder patient
PMNP-ASD	Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids	autism spectrum disorder patient
PMNP-BD	Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids	bipolar disorder patient

Primary Outcome Measures

Name	Time	Method
cortical morphology	40 minutes	Data were obtained using magnetic resonance scans
target gene charaacteristics	1 day	10ml peripheral blood was extracted for gene analysis
scale scores	90 minutes.	The score of each dimension and the total score were calculated according to the scale.The scale includes three dimensions: negative symptom, positive symptom and general psychopathology, and the score range of each dimension is different. The total score ranges from 30 to 210, with higher scores indicating worse results.

Trial Locations

Locations (1)

The Second Xiangya hospital of central south univerity; 🇨🇳 Changsha, Hunan, China